Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study

Clinical Cardiology

Volumn 41, Issue 1, 2018, Pages 13-19

  Budoff, Matthew ^a   Brent Muhlestein, J ^b,c   Le, Viet T ^b   May, Heidi T ^b   Roy, Sion ^a   Nelson, John R ^d  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d California CardioVascular Institute   (United States)

Author keywords

Atherosclerosis; Atherosclerotic Plaque; Cardiovascular Imaging Techniques; Eicosapentaenoic Acid; Icosapent Ethyl

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; LIPID; LIPOPROTEIN; PLACEBO; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; ETHYL EICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE BURDEN; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFLAMMATION; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOMARKERS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85041039155     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22856     Document Type: Article

References (43)

1. Fruchart JC, Davignon J, Hermans MP, et al; Residual Risk Reduction Initiative. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.
2. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–366.
3. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171–183.
4. Tanaka N, Ishida T, Nagao M, et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis. 2014;237:577–583.
5. Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid–enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2017. doi:https://doi.org/10.1253/circj.CJ-17-0294.
6. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–690.
7. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992.
8. Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
9. Yokoyama M, Origasa H, Matsuzaki M, et al; JELIS Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in Lancet. 2007;370:220]. Lancet. 2007;369:1090–1098.
10. BedminsterNJVascepa [package insert]. : Amarin Pharma Inc.; 2017.
11. Bays HE, Ballantyne CM, Doyle RT Jr, et al. Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016;125:57–64.
12. Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13:37–46.
13. Ballantyne CM, Bays HE, Philip S, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016;253:81–87.
14. Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635.e1–645.e1.
15. Burgstahler C, Reimann A, Beck T, et al. Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the New Age II Pilot Study. Invest Radiol. 2007;42:189–195.
16. Matsumoto S, Ibrahim R, Grégoire JC, et al. Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. Clin Cardiol. 2017;40:210–215.
17. Matsumoto S, Nakanishi R, Li D, et al. Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with metabolic syndrome in a prospective randomized double-blind study. J Nutr. 2016;146:427S–432S.
18. Nakanishi R, Ceponiene I, Osawa K, et al. Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: a propensity-score matching study. Atherosclerosis. 2016;255:73–79.
19. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression—a serial coronary CT angiography study. Atherosclerosis. 2013;231:198–204.
20. Niki T, Wakatsuki T, Yamaguchi K, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. 2016;80:450–460.
21. Dohi T, Miyauchi K, Okazaki S, et al. Plaque regression determined by intravascular ultrasound predicts long-term outcomes of patients with acute coronary syndrome. J Atheroscler Thromb. 2011;18:231–239.
22. Watanabe T, Ando K, Daidoji H, et al; CHERRY Study Investigators. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–544.
23. Gibson CM, Sandor T, Stone PH, et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol. 1992;69:1286–1290.
24. Ohnishi H, Saito Y. Eicosapentaenoic acid (EPA) reduces cardiovascular events: relationship with the EPA/arachidonic acid ratio. J Atheroscler Thromb. 2013;20:861–877.
25. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis [published correction appears in Ann Intern Med. 2014;160:658]. Ann Intern Med. 2014;160:398–406.
26. May HT, Nelson JR, Kulkarni KR, et al. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL(3)+IDL]). Lipids Health Dis. 2013;12:55.
27. Morishita T, Uzui H, Ikeda H, et al. Association of CD34/CD133/VEGFR2-positive cell numbers with eicosapentaenoic acid and postprandial hyperglycemia in patients with coronary artery disease. Int J Cardiol. 2016;221:1039–1042.
28. Shintani Y, Kawasaki T. The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography [abstract]. J Am Coll Cardiol. 2012;59:E1731.
29. Nagahara Y, Motoyama S, Sarai M, et al. The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235]. Eur Heart J. 2016;37(suppl 1):1052.
30. Alfaddagh A, Elajami T, Welty F. Omega-3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease [abstract]. Circulation. 2016;134:A16294.
31. Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006;47:1655–1662.
32. Boogers MJ, Broersen A, van Velzen JE, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. Eur Heart J. 2012;33:1007–1016.
33. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708–716.
34. Hamirani YS, Kadakia J, Pagali SR, et al. Assessment of progression of coronary atherosclerosis using multidetector computed tomography angiography (MDCT). Int J Cardiol. 2011;149:270–274.
35. Leber AW, Becker A, Knez A, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol. 2006;47:672–677.
36. Yamaki T, Kawasaki M, Jang IK, et al. Comparison between integrated backscatter intravascular ultrasound and 64-slice multi-detector row computed tomography for tissue characterization and volumetric assessment of coronary plaques. Cardiovasc Ultrasound. 2012;10:33.
37. Nakanishi K, Fukuda S, Shimada K, et al. Non-obstructive low attenuation coronary plaque predicts three-year acute coronary syndrome events in patients with hypertension: multidetector computed tomographic study. J Cardiol. 2012;59:167–175.
38. Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138–148.
39. Faergeman O, Holme I, Fayyad R, et al; Steering Committees of IDEAL and TNT trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid-Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459–463.
40. Landray MJ, Haynes R, Hopewell JC, et al; HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
41. Miller M, Cannon CP, Murphy SA, et al; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730.
42. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in N Engl J Med. 2010;362:1748]. N Engl J Med. 2010;362:1563–1574.
43. Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62:1580–1584.